NOMAD-FOODS
9.5.2022 11:43:08 CEST | Business Wire | Press release
Nomad Foods, Europe’s leading frozen food company, which owns brands including Birds Eye, Findus and iglo, is calling on the food industry and regulators across Europe to consider a more comprehensive, end-to-end approach to Life Cycle Assessment (LCA) studies, which includes food loss and waste impacts, to improve transparency for consumers and drive critical action to reduce carbon emissions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005425/en/
Food production is a major contributor to climate change and making better environmental choices about what we eat and how we reduce food waste is one way for businesses and consumers to lower their carbon impact. To support this action, it’s vital that food companies fully understand their products’ total emissions footprint and provide clear, accurate and complete information.
With carbon labels and previous LCA studies on food often limited in scope, Nomad Foods has recently enlisted the help of international experts in impact assessments, PRé Sustainability, to conduct a unique end-to-end LCA study for 22 of Nomad Foods’ most popular products1 .
Crucially, the study went beyond the scope of existing LCAs to include all stages of the product life cycle, incorporating new data on retailer and consumer food waste (an important element of Scope 3 emissions for food manufacturers) and primary data for all processing steps, improving the accuracy of the assessment – with the results peer reviewed by leading experts.
The study showed that retail and consumer food loss and waste – data which is not generally included in previous LCA assessments of food – plays an important part of the product life cycle and has a significant effect on a product’s overall environmental impact. In fact, retail and consumer food waste equates to an estimated 160m tonnes and 17.25m tonnes of CO2 in the EU and UK respectively2 .
This new assessment means that, for the first time ever, clear conclusions can be drawn about the carbon footprint of frozen foods products and meaningful comparisons made to their non-frozen alternatives, while accounting for all relevant and material impacts. Results for the 22 frozen products assessed under the new study showed that most had an equal or lower carbon footprint than similar products using other preservation methods.
Stéfan Descheemaeker, Chief Executive Officer, Nomad Foods, said: “Consumer demand for nutritious, high-quality, sustainable food is growing and we believe it’s vital that we find ways to provide consumers with information that helps them make informed choices and provides confidence that sustainability claims are robust and evidence-based. To support this, we encourage the food industry, retailers and regulators to adopt a wider scope for LCAs as standard, taking the whole product life cycle into account. Based on the ground-breaking work that our teams have undertaken with life cycle experts PRé Sustainability, we can see there are significant benefits to frozen food in terms of longer-term food preservation and reduced food waste.”
Ellen Meijer, Consultant, PRé Sustainability, said: “This is one of the most elaborate frozen food LCA studies ever done, covering not only a wide range of frozen food products and their alternatives, but also approaching them all in a consistent methodological manner. Combined with the large amount of primary production data included and the attention to detail at each stage, this study is one of a kind. Based on this study, we are now in the unique position to draw conclusions about the carbon footprint of frozen food products compared to their non-frozen alternatives and generalize these conclusions across the frozen food category."
About Nomad Foods
Nomad Foods (NYSE: NOMD) is Europe’s leading frozen food company. The company's portfolio of iconic brands, which includes Birds Eye
, Findus
, iglo
, Ledo
and Frikom
, have been a part of consumers' meals for generations, standing for great tasting food that is convenient, high quality and nutritious. Nomad Foods is headquartered in the United Kingdom. Additional information may be found at www.nomadfoods.com
.
About PRé Sustainability
For thirty years PRé Sustainability has been at the forefront of life cycle thinking and has built on its knowledge and experience in sustainability metrics and impact assessments to provide state of the art methods, consulting services and software tools. Internationally, leading organizations work with PRé to integrate sustainability into their product development procedures in order to create business growth and business value. PRé has an office in the Netherlands and a global partner network to support large international or multi-client projects. www.pre-sustainability.com
.
Notes to Editors:
1 The comprehensive LCA study covered 10 keys stages. Stages 6 – 10 are the extended scope of the assessment not generally included in other studies :
- Ingredients : Production, including transport to factory.
- Processing : All activities that happen at the factory including energy, on-site waste and the treatment of it, and activities related to packaging the product. Also includes any pre-blanching or pre-freezing before it reaches the factory. The study included primary data for all material processes improving the accuracy of the assessment.
- Packaging : Packaging materials, including their transport to the factory.
- Distribution : Transport from the factory, storage at the distribution centre, transport to the retail hub and storage at the retail hub.
- Retail storage : Electricity and coolant use in the retail cold room and on the retail floor.
- Retail waste : Waste treatment of transport packaging, product losses and waste treatment of product losses, including processing, packaging and distribution of the product losses.
- Consumer transport : From the retailer to the consumer.
- Consumer storage : Electricity use for storage at the consumer.
- Consumer preparation : Energy use at the consumer to cook the food product, as well as any capital goods.
- Consumer waste : Waste treatment of primary packaging and product losses. This includes all upstream processes required to compensate for the product losses at the consumer.
2 6.9m tonnes of the UK’s annual total of 9.5m tonnes of food waste is down to the retailer and consumer, equivalent to 17.25m tonnes of CO2 (WRAP). In the EU the retail and consumer proportion of the 88m tonnes of food waste generated, equates to 160m tonnes of CO2. Calculation based on 1 kg of food waste creates 2.5 kg of CO22013; Food Wastage Footprint Impact on Natural Resources; United Nation’s Food & Agriculture Organization
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005425/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
